Single-Inhaler Triple Therapy Utilizing the Once-Daily Combination of Fluticasone Furoate, Umeclidinium and Vilanterol in the Management of COPD: The Current Evidence Base and Future Prospects

Therapeutic Advances in Respiratory Disease - United Kingdom
doi 10.1177/1753466618760779
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Evidence-Based Review of Data on the Combination Inhaler Umeclidinium/Vilanterol in Patients With COPD

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2019English

Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2020English

A Comparison of the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol With Twice-Daily Fluticasone Propionate/Salmeterol in Moderate to Very Severe COPD

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2013English

Patient Considerations in the Treatment of COPD: Focus on the New Combination Inhaler Umeclidinium/Vilanterol

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2015English

Once-Daily Fluticasone Furoate/Vilanterol Combination Versus Twice-Daily Budesonide/Formoterol Combination in the Treatment of Controlled Stable Asthma: A Randomized Crossover Trial

Journal of Asthma and Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2019English

Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2018English

Integrated Safety and Efficacy Analysis of Once-Daily Fluticasone Furoate for the Treatment of Asthma

Respiratory Research
PulmonaryRespiratory Medicine
2016English

Fluticasone Furoate: Once-Daily Evening Treatment Versus Twice-Daily Treatment in Moderate Asthma

Respiratory Research
PulmonaryRespiratory Medicine
2011English

Safety and Tolerability of the Novel Inhaled Corticosteroid Fluticasone Furoate in Combination With the Β2agonist Vilanterol Administered Once Daily for 52 Weeks in Patients ≥12 Years Old With Asthma: A Randomised Trial

Thorax
PulmonaryRespiratory Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy